No Data
Hangzhou Jiuyuan Gene Engineering Proposes Name Change
Jiuyuan Gene (02566) plans to change its name to "Hangzhou Jiuyuan Gene Biomedical Co., Ltd."
Jiuyuan Gene (02566) announced that the Board of Directors has decided to propose changing the company's Chinese name from "Hangzhou Jiuyuan Gene Engineering Co...
Hangzhou Jiuyuan Gene Engineering's Tumor-Related Infection Drug Gets China Nod for Marketing
Announcement selection | New China Life Insurance expects a year-on-year profit increase of over 175% in 2024; LINGBAO GOLD is expected to see net income increase year-on-year by about 110% to 140%.
New China Life Insurance expects a year-on-year profit increase of over 175% in 2024; CHI MER LAND's annual sales exceed 42 billion yuan.
Jiyuan Gene (02566.HK): Jixinfen has been approved for listing by the National Pharmaceutical Administration.
On January 20, Gelonghui announced that Jiuyuan Gene (02566.HK) has received approval from the National Medical Products Administration of China for the marketing of polyethylene glycol-conjugated human granulocyte colony-stimulating factor injection (trademark name: Jixinfen). It is used to treat adult patients with non-myeloid malignant tumors undergoing myelosuppressive anticancer drug treatment that may cause febrile neutropenia, aimed at reducing the incidence of infections manifested by febrile neutropenia. Jixinfen is obtained by crosslinking human granulocyte colony-stimulating factor (hG-CSF) with 20KD polyethylene glycol, resulting in a significantly prolonged half-life, enhanced biological stability, and resistance to enzymatic degradation.
Express News | Hangzhou Jiuyuan Gene Engineering - Marketing Registration of Jixinfen Approved by Nmpa
